Grant is a seasoned pharmaceutical and biotech executive with over 30 years of experience across vaccines and immunotherapeutic drug development and commercialization, as well as the successful formation and financing of multiple platform companies. Prior to founding Vaxcyte in 2013, Grant served as the CEO of Mymetics Corporation, a European-based vaccine company developing a prophylactic RSV vaccine based on a virosomal platform technology. Previously, he was an executive-in-residence at Kleiner, Perkins, Caufield & Byers, while also serving as the CEO at Juvaris BioTherapeutics. Under his leadership, Juvaris’ immunotherapeutic and vaccine adjuvant platform yielded multiple animal health products, launched by its alliance partner Bayer HealthCare, including Zelnate® and Victrio®. Prior to Juvaris, Grant spent a number of years at Dendreon Corporation, playing a prominent role in the company’s IPO and run-up to commercialization. During his tenure, he led Dendreon’s clinical development, operations, manufacturing, business development and project management functions, culminating in the launch of the therapeutic prostate cancer vaccine, Provenge®. He also led marketing and business development for the pain management platform company, Algos Pharmaceutical Corporation, which was acquired by Endo Pharmaceuticals. Grant began his career at Glaxo and Johnson & Johnson in sales, marketing, and clinical research roles. Grant currently serves on the board of directors of Athira Pharma, Inc. He earned his BS degree in marketing from The Pennsylvania State University and his MBA from Georgetown University with high honors.

• 

  Co-Founder in Vaxcyte

  Vaccine Innovation. Beyond Convention.

• 

  Board of Director in Vaxcyte

  Vaccine Innovation. Beyond Convention.

• 

  Chief Executive Officer (CEO) in Vaxcyte

  Vaccine Innovation. Beyond Convention.